




## Colorectal cancer screening: an international viewpoint




**Mark Elwood, BC Cancer Agency  
Previously Director, National Cancer  
Control Initiative, Australia**



Cette présentation a été effectuée le 26 octobre 2006, au cours du Symposium "La santé publique et le dépistage du cancer : espoirs et réalités" dans le cadre des Journées annuelles de santé publique (JASP) 2006. L'ensemble des présentations est disponible sur le site Web des JASP, à l'adresse <http://www.inspq.qc.ca/jasp>.



## Survival by stage: South Australia



## Screening using faecal occult blood tests

### *Four randomised trials:*

- Minnesota USA hydrated tests, volunteer group, started 1975, published 1993
- Nottingham UK general practice pop, started 1981, published 1996
- Funen, Denmark; general pop, started 1985, published 1996
- Gothenburg, Sweden; general pop, started 1982, published 1994



## **AHTAC (Aust Hlth Tech Advisory Comm) report on screening for bowel cancer – Dec 1997**

*Australia should develop a program for colorectal cancer screening by FOBT for the average-risk population (well population aged over 50)*

*The program should commence with preliminary testing involving a number of pilot and feasibility studies*



## **National Cancer Control Initiative proposals for a pilot study, 1998, 99**

**Involving 200+ stakeholders:**

- Deliver the screening program within the existing system for service delivery
- Ensure high quality care
- Have a smooth interface between screening and diagnostic follow-up
- Collect robust data and develop and maintain a register



# National Cancer Control Initiative proposals for a pilot study, 1998, 99

## Some issues:

- Avoid the word 'research'
- Invitation process from health insurance; reqd legislation
- Pilot areas decided by demographics
- Pilots to be managed directly by federal health department



- European results published 1996
- AHTAC report 1997
- Proposals for pilot studies 1998, 1999




- European results published 1996
- AHTAC report 1997
- Proposals for pilot studies 1998, 1999
- Peer-reviewed cancer clinical guidelines recommend biennial FOBT age 50 y and older, 1999
- Cancer Strategies Group highlights CRC screening as a priority, and conducts economic analysis: estimate \$16,000 per DALY gained.



- Federal funding for pilot in budget May 2000
- Pilot projects start Nov 2002 – April 2003



## Pilot sites



Subjects aged 50-74; one round of biennial screening; two immunochemical tests compared.  
Total invited 57,000





## FEATURES OF THE PILOT

- Register based within the federal Health Insurance Commission
- Invitation and kits mailed to total of 57,000 people aged 55-74 in three areas chosen on demographic criteria; one reminder at 6 wks
- Self testing kits returned by mail
- Two immunochemical tests (Bayerdetect and !nform) compared
- FOBT results sent to participants, GPs and central register
- Phone helpline set up





## Bayer Detect



## !nform (Enterix)



Both tests require samples from each of two bowel motions.

## Immunochemical tests

Faeces

Hemoglobin

Heme

Globin

Guaiac; peroxidase.

Interference by  
Meat, vegies, vitamin C, NSAIDs.

Detects bleeding from  
Stomach, small & large intestine.

chemical

From: Prof G Young

Immunochemical.: specific  
to human globin

No interference.

Detects bleeding from  
large intestine.

immuno

INITIATIVE

## Advantages of immunochemical tests

- *Make it easier for screenee and improve participation*
  - **Remove need for diet and drug restriction**
- *Improve sensitivity*
- *Improve specificity*
  - **Selectively target colonic bleeding**
  - **Avoid diet and drug interference**
- *Improve discrimination and quality control*



### **Easier-to-read endpoint**

- **Allow quantification**
- **Allow automation**

*From: Prof G Young*

## Guaiac tests

- **How to prepare for the test:**
- Do not consume red meat, any blood-containing food, cantaloupe, uncooked broccoli, turnip, radish, or horseradish for 3 days prior to the test.
- You may need to discontinue drugs that can interfere with the test such as vitamin C and aspirin if possible. Check with your health care provider regarding medication changes that may be necessary.




## Participation


- 56,907 invitations issued
- 25,840 (45.4%) completed FOBTs
- Mackay 57.5%, Adelaide 46.3%, Melbourne 39.9%
- Participation higher with Bayer detect 47.2% than Inform 43.6%
- Only local publicity




## Participation by age & sex




## Participation by centre



## Participation by socio-economic group (post code)



## Participation by preferred language




## Positivity rates

- 56,007 invitations issued
- 27,064 (45.4%) completed FOBTs
- 25,668 (95%) satisfactory
- **Positivity rate 9.0 %**
- Positivity Bayer detect 8.2%, Inform 9.9%



## Positivity by age, sex and test: overall 9%



## Available data on subjects with positive tests

### Colonoscopy (n = 1265)

- Cancer: 67 (5.3%)
- Advanced adenoma: 176 (13.8%)



## Available data on 2308 subjects with positive tests

### Colonoscopy (n = 1265)

- Cancer: 67 (5.3%)
- Advanced adenoma: 176 (13.8%)

### Unknown outcome (n = 1035)

- No results retrieved for 1035



## Colonoscopy referral in pilot: Adelaide

Positive FIT, n=1437	Referred for colonoscopy	Referred for other	No referral
Males	93.4%	1.8%	4.8%
Females	93.7%	2.3%	4.0%



*From: Prof G Young*

## Colonoscopy waiting times – pilot: Adelaide

Phase of activity	Days waiting		
	Mean	Median	Maximum
Consultation to colonoscopy (d)	38.5	30	394



*From: Prof G Young*

## Available data on all subjects with colonoscopy

### Positive FOBT (n = 1265)

- Cancer: 67 (5.3%)
- Advanced adenoma: 176 (13.8%)
- Other adenoma 75 (5.9%)

### Other referral by GP (n = 529)

- Cancer: 2 (0.4%)
- Advanced adenoma: 19 (3.4%)
- Other adenoma 21 (4.0%)





## Conclusions from pilot studies

- Participation rates adequate, given little publicity
- Positivity rate high
- Referral for colonoscopy without positive FOBT of little value
- Symptom history not predictive – omit; FH only limited value
- Data systems for invitation reasonable
- Data systems for follow up inadequate



## Some problem areas identified in pilot

- Invitation and consent package – too much information
- Collection of data – incomplete, slow
- Follow up safety net – clinical data system inadequate
- Communications between register, participants and clinicians often poor
- Quality issues related to colonoscopy and histopathology




## Estimated cost-effectiveness

- Lifetime cost per life year gained \$24,000
- Comparisons: breast screening \$ 13,000
- cervix screening \$ 44,000



## No-one likes sampling faeces



Hemocult



- This applies to specialists, family doctors, managers, and politicians also!



Dr Michael Woodridge, Australian federal minister of health:




Dr Michael Woodridge, Australian federal minister of health:

*“It took me five budgets to get the bowel screening program. I don’t think they thought paying someone to have something stuck up their bum would be politically popular”*

From: S, Maiden in ‘The Howard Factor’, Melbourne Univ Press, 2006





## National Program

- Screening is resourced federally from funds separate to other medical care
- Federal funding to initiate the national bowel cancer screening program: \$43 million over 4 years, 2005 budget.
- Uses Bayer immunochemical test, every 2 yrs. This is free. Follow-up colonoscopies in public sector, or private (likely some patient payment).



NATIONAL  
CANCER  
CONTROL  
INITIATIVE

## Current Eligibility Criteria

- People who:
  - are turning 55 or 65 years of age between May 1, 2006 and June 30, 2008, or
  - (Plus those were invited to participate in the Pilot Program)
  - This is 12 % of target group aged 55-74



## Some diversions on the way...

- Recommended that screening for indigenous population (ATSI) should start at age 45



## Current initial National Program

- 380,000 people to be invited over 2 yrs
  - 230,000 55 year olds
  - 150,000 65 year olds

- Anticipated participation rate - 50%

- Anticipated FOBT positivity rate - 8%

Thus, 7500 colonoscopies needed per year: 150 per week

500 accredited colonoscopists: < 1 extra per week each

\*\* screening only; ignores follow up



## Future annual workload

3,200,000 Australians aged 55-74 years.

***FOBT screening (biennial, 50% uptake; 8% positivity rate)***

64,000 colonoscopies; 128 complications

2-3 extra scopes per week per colonoscopist

***Colonoscopic screening (10-yearly)***

160,000 colonoscopies (50% uptake); 320 complications

6-7 extra scopes per week per colonoscopist

Ignores follow up



## Follow up of those with adenomas

- Finding adenomas currently means on-going surveillance
  - Threshold for surveillance has huge impacts
  - Limited evidence-base for follow-up frequency



**Conclusions**





## Australian experience

- Objective has been to produce a whole population, cost controlled, centrally organised and monitored program




## Issues of central control

- All funding steps have required specific items in the annual federal budget
- Evidence of benefit – 1996
- Aust recommendation to proceed – 1998
- Pilot program protocol – 1998, 1999
- Funding for pilot – 2000
- Pilot starts – 2002
- Pilot finishes – 2005
- Program for 12% of eligible group starts, 2006



Pilot studies of colorectal cancer screening: \$2 million per year for 4 years  
Health care costs of colorectal cancer: \$200 million per year  
**Increase in costs of colonoscopies: \$4 million per year**



## Australian experience

- Objective has been to produce a whole population, cost controlled, centrally organised and monitored program
- Alternative would be making tests and follow up available with subsidy on the Medical Benefits Schedule, and educate the public, family doctors, and specialists



## A contrast

- USA experience
- Prop of pop screened in 2004 - 57%  
(FOBT 1 yr 18.7, endoscopy 10 yr 50.6)
- Australian experience
- Prop of pop screened in 2006 - <10 % ?



**Thank you**

**[melwood@bccrc.ca](mailto:melwood@bccrc.ca)**



